| References |
Top |
| REF 1 |
pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases. Mol Cells. 2012 Feb;33(2):195-201.
|
| REF 2 |
Regulation of the transcriptional activation of the androgen receptor by the UXT-binding protein VHL. Biochem J. 2013 Nov 15;456(1):55-66.
|
| REF 3 |
Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL. Oncogene. 2017 Jun 15;36(24):3450-3463.
|
| REF 4 |
Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. J Biol Chem. 2005 Jun 10;280(23):22205-11.
|
| REF 5 |
Von Hippel-Lindau regulates interleukin-32 stability in ovarian cancer cells. Oncotarget. 2017 Jul 17;8(41):69833-69846.
|
| REF 6 |
p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell. 2006 May 5;22(3):395-405.
|
| REF 7 |
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998 Jun;1(7):959-68.
|
| REF 8 |
Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509.
|
| REF 9 |
Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2/androgen receptor signals. Oncotarget. 2015 Sep 29;6(29):27555-65.
|
| REF 10 |
Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2002 Feb 15;277(7):4656-62.
|
| REF 11 |
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 1999 Jul 15;13(14):1822-33.
|
| REF 12 |
Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway. Oncogene. 2006 May 18;25(21):3079-83.
|
| REF 13 |
Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol. 2007;3:89.
|
| REF 14 |
The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity. Nat Cell Biol. 2012 Jan 29;14(2):201-8.
|
| REF 15 |
Proteomic dissection of the von Hippel-Lindau (VHL) interactome. J Proteome Res. 2011 Nov 4;10(11):5175-82.
|
| REF 16 |
Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene. 2005 Nov 24;24(53):7850-8.
|
| REF 17 |
Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6459-63.
|
